Ceapro Inc.

120 articles about Ceapro Inc.

• Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

  11/27/2023

  Ceapro Inc.  (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”) announced today the initiation of its Phase 1 study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.

• Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology

  11/7/2023

  Ceapro Inc. announced the signing of a technical collaboration with Austria-based NATEX Prozesstechnologie GmbH to accelerate the scale-up of its proprietary PGX Technology towards commercial level.

• Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update

  8/29/2023

  Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2023.

• Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise

  8/25/2023

  Ceapro Inc. announced the signing of an amendment to its long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market.

• Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation

  7/18/2023

  Ceapro Inc. announced today the expansion of its collaboration with the Angiogenesis Foundation to conduct research on characterizing healing dynamics and molecular profiling of tissue regeneration stimulated by oat-derived bioactives.

• Ceapro to Participate in the Virtual Investor Summer Spotlight SeriesLive moderated video webcast on Wednesday, July 12th at 1:00 PM ET

  7/5/2023

  Ceapro Inc. announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro and Dr. Vincent W. Li, Chief Operating Officer and Scientific Director of the Angiogenesis Foundation will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 1:00 PM ET.

• Ceapro Announces Results of 2023 Shareholders’ Meeting

  6/7/2023

  Ceapro Inc. announced that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June 6, 2023 as per the following results.

• Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

  5/25/2023

  Ceapro Inc.(TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

• Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

  5/23/2023

  Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”) today announced encouraging results from it’s completed pre-clinical CHRP study conducted with McMaster University evaluating PGX-processed yeast beta glucan (PGX-YBG) as a potential therapeutic option for individuals suffering from interstitial lung diseases (ILD).

• Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration

  5/3/2023

  Ceapro Inc. announced positive results from a research collaboration with the Angiogenesis Foundation conducted with colleagues at the University of Arizona.

• Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations

  4/27/2023

  Ceapro Inc. today announced the appointment of Michel (Mitch) Regnier as Senior Vice President, Technical Operations, effective May 1, 2023.

• Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights

  4/12/2023

  Ceapro Inc.(TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.

• Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference

  3/23/2023

  Ceapro Inc. announced that the abstract titled, “Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis,” has been accepted for a presentation at the American Thoracic Society International Conference to be held at the Walter E. Washington Convention Center in Washington, DC between May 19-24, 2023.

• Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society

  3/8/2023

  Ceapro Inc. (TSX-V: CZO;OTCQX: CRPOF) (“Ceapro” or the “Company”) announced today that the abstract titled “Application of Avena Sativa Derived Therapeutics β-Glucan and Avenanthramide Accelerate Wound Healing in Mice Via Angiogenic and Anti-inflammatory Mechanisms,” has been accepted for a presentation at the Annual Meeting of the Wound Healing Society (WHS) to be held at the National Harbor, MD Conference Center between April 26-29, 2023.

• Ceapro to Present at the Virtual Investor 2023 Companies to Watch EventLive video webcast on Wednesday, January 18th at 3:00 PM ET

  1/10/2023

  Ceapro Inc. today announced that Gilles Gagnon, M.Sc., MBA, President and Chief Executive Officer of Ceapro, will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 3:00 PM ET.

• Ceapro Announces Grant of Stock Options - Jan 04, 2023

  1/4/2023

  Ceapro Inc., a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced the granting of stock options to employees, officers and directors of the Company.

• Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets

  12/22/2022

  Ceapro Inc. today announced it has received approval from Health Canada to initiate its Phase 1/2a study evaluating the safety, tolerability, bioavailabilty and efficacy of its pharmaceutical grade tablet of avenanthramide as a potential anti-inflammatory product.

• Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights

  11/9/2022

  Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2022.

• Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

  11/7/2022

  Ceapro Inc. announced the signing of a license agreement with The Governors of the University of Alberta to use designated areas within Agri-Food Discovery Place to further scale up the Company’s disruptive Pressurized Gas eXpanded technology in preparation for commercial partnerships.

• Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

  10/13/2022

  Ceapro Inc.  today announced positive results from its collaborative project led by Dr. Donna Vine, Professor at the Department of Agriculture, Food and Nutritional Science of University of Alberta.